MigraineMind research summary

PRMT8 Alleviates Nitroglycerin-Induced Migraine in Mice Through Inhibiting NF-κB Pathway.

Pain Res Manag | 2026

Laboratory / animal study
AuthorsZhang A, Zhao W, He H, Chen H, Liu Y
JournalPain Res Manag
Publication year2026
PubMed ID43061769

Summary

This study investigated how protein arginine methyltransferase 8 (PRMT8) affects migraines. Researchers created a migraine model in mice by injecting nitroglycerin (NTG). They measured pain sensitivity using mechanical and thermal tests. Additionally, they stimulated BV2 cells with LPS to study inflammation. The team looked at PRMT8 levels and several related proteins, including calcitonin gene-related peptide (CGRP) and NF-κB signaling pathways. They found that PRMT8 levels decreased in microglia after NTG injection. When PRMT8 was overexpressed, it improved migraine-like symptoms and reduced inflammation. This suggests that PRMT8 might play a protective role against migraines by inhibiting certain inflammatory pathways. Overall, this research highlights the potential of targeting PRMT8 for migraine treatment. It opens the door for new therapies that could reduce migraine pain and improve quality of life for patients. Clinical relevance: This research indicates that enhancing PRMT8 could offer new migraine treatments by reducing inflammation and pain pathways.

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.